Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company focused on medicines for genetically defined conditions. This news page aggregates company announcements, press releases and event updates so readers can follow how BioMarin’s strategy, pipeline and commercial portfolio evolve over time.
Recent communications from BioMarin highlight its emphasis on Enzyme Therapies and Skeletal Conditions business units, as well as its work with ROCTAVIAN, a gene therapy for hemophilia A. The company issues news on topics such as financial results, long-term guidance, corporate strategy, business development transactions, clinical data presentations and regulatory milestones for its therapies.
Examples of news themes include updates on VOXZOGO in achondroplasia and other skeletal conditions, progress with PALYNZIQ in phenylketonuria, development of BMN 401 for ENPP1 deficiency and other pipeline programs in rare genetic diseases. BioMarin also reports on strategic partnerships, such as digital and data collaborations, and on planned acquisitions intended to expand and diversify its rare disease portfolio.
Investors and followers of BMRN can use this page to review earnings announcements, conference presentations, investor day materials and product-specific updates released through newswires. By checking this feed regularly, readers can see how BioMarin describes its growth priorities, clinical milestones and capital allocation decisions across its rare disease franchises.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has received Fast Track designation from the U.S. FDA for BMN 307, a gene therapy aimed at treating phenylketonuria (PKU). This designation will expedite the drug's development and review processes. The company's Phase 1/2 study, Phearless, is underway, evaluating the safety and efficacy of a single dose of BMN 307. With over 15 years in PKU research and two existing therapies, BioMarin aims to provide further treatment options. The Fast Track status may allow for Accelerated Approval and Priority Review.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced that Brian Mueller, Executive Vice President and Chief Financial Officer, will participate in Morningstar's Management Behind the Moat Conference on September 30, 2020, at 1:00 PM ET. The conference will be accessible through a live audio webcast, which can be found on the company's investor relations website. An archived version will also be available for a limited time. BioMarin specializes in developing therapies for serious rare disorders and has six commercial products along with several candidates in its portfolio.
BioMarin Pharmaceutical (BMRN) has initiated the global PHEARLESS Phase 1/2 study by dosing the first participant with BMN 307, a gene therapy aimed at treating phenylketonuria (PKU). This investigational treatment seeks to normalize blood phenylalanine (Phe) levels by delivering a functional PAH gene. Both the FDA and EMA have granted Orphan Drug Designation to BMN 307, which represents a significant addition to BioMarin's PKU treatment portfolio. The study will assess the therapy's safety and efficacy, marking a crucial step in addressing the unmet needs of PKU patients.
BioMarin Pharmaceutical (NASDAQ: BMRN) will participate in four upcoming virtual investor conferences, as announced on September 15, 2020. Management will deliver presentations, available via audio webcast, on the company's innovative therapies for serious rare disorders. Interested parties can access the live webcast and an archived version through the company’s investor relations website. BioMarin's portfolio includes six commercialized products, with several candidates in clinical and pre-clinical stages. For more details, visit www.biomarin.com.
BioMarin Pharmaceutical has announced that data from its Phase 3 trial of vosoritide, aimed at treating achondroplasia in children aged 5-18, will be presented at the ASBMR Annual Meeting on September 12, 2020. This randomized, double-blind study involved 121 children and focused on growth velocity changes over one year. Vosoritide has received orphan drug designation from the FDA and EMA. The trial is part of a robust clinical program targeting a condition affecting 1 in 25,000 live births, with no current approved treatments in major markets.
BioMarin Pharmaceutical announced results from a Phase 3 trial of vosoritide, an investigational therapy for achondroplasia, published in The Lancet. Conducted on children aged 5-18, the trial showed that daily subcutaneous vosoritide significantly improved annualized growth velocity (AGV) by 1.57 cm/year compared to placebo (p 0.0001). Additionally, height Z scores increased by +0.28 (p < 0.0001). The therapy was generally well tolerated with mild adverse effects. BioMarin plans to collaborate with regulatory authorities for potential marketing approvals, addressing a significant unmet medical need.
BioMarin Pharmaceutical (NASDAQ: BMRN) will participate in two virtual investor conferences, as announced on September 8, 2020. An audio webcast of the presentations will be available live, with access through their investor website. Archived versions of the remarks will also be provided for a limited time post-conference. BioMarin is a global biotechnology company focused on rare disorders, with six commercial products and several candidates in clinical development.
BioMarin Pharmaceutical (BMRN) announced the submission of a New Drug Application (NDA) to the FDA for vosoritide, a potential treatment for children with achondroplasia. This regulatory move follows the validation of the Marketing Authorization Application (MAA) by the EMA on Aug. 13, 2020. Vosoritide represents a significant milestone as the first pharmacological treatment option for this condition, which affects children characterized by disproportionate short stature. The drug is currently being tested in children under 18 with open growth plates, comprising 25% of achondroplasia cases.
BioMarin Pharmaceutical announced that the FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application for valoctocogene roxaparvovec gene therapy for severe hemophilia A on August 18, 2020. The FDA's CRL indicated that additional data, specifically two years from the ongoing Phase 3 study, is required to demonstrate the therapy's durability of effect. Although BioMarin plans to meet with the FDA to discuss next steps, the company's previous expectations were altered with this new requirement. The European Medicines Agency's review of the therapy is still ongoing.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced validation from the European Medicines Agency (EMA) for its Marketing Authorization Application (MAA) for vosoritide, a treatment aimed at children with achondroplasia, a common form of disproportionate short stature. The MAA review began on August 13, 2020. The company is also set to submit a New Drug Application (NDA) to the FDA in the third quarter of 2020. Vosoritide offers potential as the first pharmacological intervention for achondroplasia, which affects one in 25,000 live births globally.